- Investing.com
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Metrics to compare | ERAS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipERASPeersSector | |
|---|---|---|---|---|
P/E Ratio | −34.2x | −4.0x | −0.5x | |
PEG Ratio | −0.82 | −0.10 | 0.00 | |
Price/Book | 12.6x | 3.1x | 2.6x | |
Price / LTM Sales | - | 65.5x | 3.2x | |
Upside (Analyst Target) | 12.9% | 70.2% | 53.2% | |
Fair Value Upside | Unlock | 18.3% | 7.6% | Unlock |